CIBC Private Wealth Group
BBOT

CIBC Private Wealth Group’s BridgeBio Oncology BBOT Stock Holding History

CIBC Private Wealth Group’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$62.6K Buy
+5,000
New +$60.6K ﹤0.01% 1695

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

CIBC Private Wealth Group's BBOT Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in BridgeBio Oncology (BBOT) in Q4 2025: 5,000 shares worth $62.6K. The stake represents ﹤0.01% of the portfolio and ranks #1695 among its holdings.

53 funds tracked by Wall St. Rank hold BBOT as of Q4 2025.

  • CIBC Private Wealth Group held 5,000 shares of BridgeBio Oncology worth $62.6K as of Q4 2025.
  • BridgeBio Oncology was a new CIBC Private Wealth Group position in Q4 2025.
  • BridgeBio Oncology made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1695 holding.
  • 53 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.